Senate investigations panel to probe
Mylan's EpiPen pricing
Send a link to a friend
[September 08, 2016]
WASHINGTON (Reuters) - The U.S.
Senate's permanent subcommittee on investigations will probe Mylan
Pharmaceuticals' pricing of the allergy auto-injector EpiPen, according
to a press release issued on Wednesday.
The release described the probe as a "preliminary inquiry."
Mylan has been criticized - including by Democratic presidential
candidate Hillary Clinton - for sharply raising the price of EpiPens,
which are carried by people with life-threatening allergies. Mylan
raised the price from about $100 in 2008 to about $600 currently. It has
offered some discounts but this has done little to allay concerns.
"Our review of this matter will be robust, thorough, and bipartisan.
Parents and school districts in Ohio, Missouri and across the country
need affordable access to this life-saving drug, and we share their
concern over Mylanís sustained price increases," Senators Rob Portman,
the Republican chair of the subcommittee, and Claire McCaskill, the top
Democrat, said in a statement.
[to top of second column]
EpiPen auto-injection epinephrine pens manufactured by Mylan NV
pharmaceutical company for use by severe allergy sufferers are seen
in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo
Mylan did not immediately respond to a request for comment.
(Reporting by Diane Bartz; Editing by Chris Reese and Andrew Hay)
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.